Objective: Sarcomas are a group of rare malignancies with various subtypes. Patients with
metastatic sarcoma who have failed traditional treatments can possibly achieve better …

Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity
among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of …

Purpose Programmed cell death 1 (PD-1) inhibitors are ineffective as monotherapy for the
treatment of soft tissue sarcomas (STS). However, increasing evidence shows that the …

Purpose Although both anti-PD-1 antibody and treatments using anti-PD-L1 antibody are
currently in clinical use, their therapeutic effects vary according to cancer type. One of the …

Background Sarcomas constitute a heterogeneous group of tumors with different clinical
behaviors and variable responses to systemic therapies. Recent immunotherapy studies …

In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated
expression and clinical relevance of programmed cell death-1 (PD-1), programmed death …

Background: Programmed cell death 1 ligand-1 (PD-L1) is an immune checkpoint molecule
that acts to protect cancer cells from immune surveillance and is considered as a prognostic …

Programmed cell death-ligands 1 (PD-L1) is a key immune checkpoint protein and a
promising therapeutic target for malignancy tumor immunotherapy. The prognostic value of …

Although there exist manifold strategies for cancer treatment, researchers are obliged to
develop novel treatments based on the challenges that arise. One of these recent treatment …

Objective: To investigate the efficacy and safety of antiangiogenesis-immunotherapy therapy
in patients with advanced STS in China, and to explore the potential factors of prognosis …